Greenyn Biotechnology , Ltd Return on Equity

Greenyn Biotechnology , Ltd's return on equity stands at 13.86%. That is above the Healthcare sector average of 13.26%. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Greenyn Biotechnology , Ltd sits higher the Healthcare benchmark (13.26%) with a ROE of 13.86%. That is roughly 4.5% above the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.

A ROE of 13.86% for Greenyn Biotechnology , Ltd means each unit of related capital or sales is generating that return rate. Higher is usually better for profitability metrics, but extremely high figures can reflect one-time items or thin equity bases. Review several years of data on this page before extrapolating.

The history chart shows how Greenyn Biotechnology , Ltd's ROE evolved across reporting periods, while the comparison chart places 6846.TWO next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, ROE is commonly used to spot outliers. Greenyn Biotechnology , Ltd's reading of 13.86% (sector avg 13.26%) is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.